1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Cogstate Limited
  6. News
  7. Summary
    CGS   AU000000CGS8

COGSTATE LIMITED

(CGS)
  Report
Delayed Australian Stock Exchange  -  05/16 02:11:03 am EDT
1.715 AUD   +3.94%
04/20COGSTATE : Investor Update
PU
04/20COGSTATE : Business Update and March 2022 Quarter Cashflow
PU
03/20COGSTATE LIMITED(ASX : CGS) added to S&P/ASX Emerging Companies Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cogstate : Clinical Trial in Dementia with Lewy Bodies Used Cogstate Digital Assessments and Data Quality Services to Support the Evaluation of Neflamapimod

11/29/2021 | 02:11pm EDT
Study Demonstrated Neflamapimod Improved Cognition, Motor Function and Dementia Progression Relative to Placebo

Neuroscience technology company, Cogstate Ltd (ASX.CGS), announced its digital cognitive assessments were part of the primary endpoint in the AscenD-LB study, a phase 2 clinical trial in Dementia with Lewy Bodies (DLB) conducted by EIP Pharma Inc. The company announced final results of the trial, which demonstrated neflamapimod treatment led to significant improvement relative to placebo in cognition, functional mobility and dementia progression in patients with DLB.

DLB is the second most common form of dementia, and currently there are no treatments available for the disease. The AcendD-LB trial results represent a possible breakthrough in development of a therapeutic candidate for individuals impacted by DLB worldwide.

The primary objective of the AscenD-LB study was to evaluate the effect of neflamapimod, an oral investigational drug, on cognition, as measured by Cogstate digital assessments (Detection, Identification, One Card Learning, One Back, Verbal Fluency and Category Fluency).

Secondary endpoints included the ten-item Neuropsychiatric Inventory (NPI), Timed Up and Go test (TUG), and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), for which Cogstate provided comprehensive data quality services including rater training and central monitoring.

"For years, strategies to treat neurodegenerative diseases have sought to support cholinergic neurotransmission in the basal forebrain," said Dr. Paul Maruff, Cogstate Chief Innovation Officer. "This is a remarkable finding that for people with DLB treatment with the drug neflamapimod-proposed to restore the function of basal forebrain cholinergic neurons though inhibition of p38α kinase-resulted in substantial improvement on the measures of attentional function, as shown via the Cogstate battery. This success reflects innovation and precision in preclinical development and clinical translation of the drug. It also provides a strong foundation for further development of neflamapimod as a treatment for DLB. Congratulations to the team at EIP Pharma and to all of the patients, caregivers and clinicians who contributed to this trial."

Read the press release from EIP Pharma here: https://bit.ly/3HN9ybF

About Cogstate Ltd.
Cogstate Ltd. (ASX:CGS) is a neuroscience technology company focused on optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate pioneers rapid, reliable and highly sensitive digital cognitive testing technologies, and delivers data quality services for clinical outcome assessments that combine scientific insights, innovative operational approaches and advanced analytics. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.

Media Inquiries
Rachel Colite - rcolite@cogstate.com

Back to News

Disclaimer

CogState Ltd. published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 19:10:02 UTC.


ę Publicnow 2021
All news about COGSTATE LIMITED
04/20COGSTATE : Investor Update
PU
04/20COGSTATE : Business Update and March 2022 Quarter Cashflow
PU
03/20COGSTATE LIMITED(ASX : CGS) added to S&P/ASX Emerging Companies Index
CI
03/20COGSTATE LIMITED(ASX : CGS) added to S&P/ASX All Ordinaries Index
CI
02/24TRANSCRIPT : Cogstate Limited, H1 2022 Earnings Call, Feb 24, 2022
CI
02/23COGSTATE : Half Year Report – H1 FY2022
PU
02/23COGSTATE : 1H22 Financial Results & Business Update
PU
02/23COGSTATE : Investor Briefing
PU
02/23COGSTATE : App 4D and Financial Statements Half-year Ended 31 Dec 2021
PU
02/23COGSTATE : Appendix 4D and Financial Statements for Half-year Ended 31 December 2021
PU
More news
Financials
Sales 2022 63,5 M 43,9 M 43,9 M
Net income 2022 10,3 M 7,14 M 7,14 M
Net cash 2022 30,2 M 20,9 M 20,9 M
P/E ratio 2022 28,7x
Yield 2022 -
Capitalization 297 M 206 M 206 M
EV / Sales 2022 4,21x
EV / Sales 2023 2,95x
Nbr of Employees 171
Free-Float 46,9%
Chart COGSTATE LIMITED
Duration : Period :
Cogstate Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COGSTATE LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,72 AUD
Average target price 2,88 AUD
Spread / Average Target 67,9%
EPS Revisions
Managers and Directors
Bradley John O'Connor Chief Executive Officer, Executive Director & MD
Darren Watson Chief Financial Officer
Martyn Kenneth Myer Non-Executive Chairman
Chris Edgar Chief Scientific Officer
Benjamin Bloomfield Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
COGSTATE LIMITED-31.82%198
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153